A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

• Drug: PF-04991532
  
  Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
• Drug: PF-04991532
  
  Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
• Drug: PF-04991532
  
  Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
• Drug: PF-0499132
  
  Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
• Drug: Placebo
  
  Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days

• Experimental: PF-04991532
  
  PF-04991532 experimental study medication
  Interventions:
  

  • Drug: PF-04991532
  • Drug: PF-04991532
  • Drug: PF-04991532
  • Drug: PF-0499132
• Placebo Comparator: Placebo
  
  PF-04991532 Matching Placebo
  Intervention: Drug: Placebo

Inclusion Criteria:

• Patients with type 2 diabetes mellitus who are taking either no medication for the treatment of diabetes (diet/exercise therapy only), or who are taking only a single oral anti-diabetic drug (OAD) that can be temporarily discontinued for approximately 8-10 weeks. For those taking a single OAD, treatment should be stable, where this is defined as no change in the treatment, including dose, over the past 3 months prior to Screening. OAD medications that are acceptable to be discontinued include: a sulfonylurea (SU), a meglitinide, a biguanide (eg, metformin), a dipeptidyl peptidase 4 inhibitor (DPP-4i), or an alpha glucosidase inhibitor.
• Body Mass Index (BMI) of 18.5 to 45.0 kg/m2; and a total body weight >50 kg (110 lbs).
• HbA1c >/=7% and /=6.5% and

Exclusion Criteria:

• Evidence or history of diabetic complications with significant end organ damage.
• History of stroke or transient ischemic attack.
• History of myocardial infarction.
• History of coronary artery bypass graft or stent implantation.
• Clinically significant peripheral vascular disease.
• Any history or clinical evidence of congestive heart failure, NYHA Classes II IV.
• Current history of angina/unstable angina.
• One or more episodes of hypoglycemia within the last 3 months, or two or more episodes of hypoglycemia within the last 6 months.
• A positive urine drug screen.
• Use of tobacco or nicotine-containing products in excess of the equivalent of 10 cigarettes per day.
• Blood pressure >/=160 mm Hg (systolic) or >/=100 mm Hg (diastolic), following at least 5 minutes of rest.
• Pregnant or nursing females; females of childbearing potential.